

Maria H Madeira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/613679/publications.pdf>

Version: 2024-02-01

27
papers

858
citations

686830

13
h-index

580395

25
g-index

27
all docs

27
docs citations

27
times ranked

1139
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of Microglia-Mediated Neuroinflammation to Retinal Degenerative Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-15.	1.4	196
2	Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury. <i>Translational Research</i> , 2016, 169, 112-128.	2.2	74
3	Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure. <i>Journal of Neuroinflammation</i> , 2015, 12, 115.	3.1	73
4	Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. <i>Mediators of Inflammation</i> , 2017, 2017, 1-12.	1.4	57
5	Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma. <i>Scientific Reports</i> , 2016, 6, 27532.	1.6	54
6	Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage. <i>Cell Death and Disease</i> , 2017, 8, e3065-e3065.	2.7	53
7	Blockade of microglial adenosine A _{2A} receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. <i>Glia</i> , 2019, 67, 896-914.	2.5	51
8	Blockade of microglial adenosine A2A receptor impacts inflammatory mechanisms, reduces ARPE-19 cell dysfunction and prevents photoreceptor loss in vitro. <i>Scientific Reports</i> , 2018, 8, 2272.	1.6	44
9	Keep an eye on adenosine: Its role in retinal inflammation. , 2020, 210, 107513.		34
10	Transient Downregulation of Melanopsin Expression After Retrograde Tracing or Optic Nerve Injury in Adult Rats. , 2015, 56, 4309.		25
11	Retinopathy Phenotypes in Type 2 Diabetes with Different Risks for Macular Edema and Proliferative Retinopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1433.	1.0	21
12	Swept-source OCTA quantification of capillary closure predicts ETDRS severity staging of NPDR. <i>British Journal of Ophthalmology</i> , 2022, 106, 712-718.	2.1	20
13	Standardization of Optical Coherence Tomography Angiography Imaging Biomarkers in Diabetic Retinal Disease. <i>Ophthalmic Research</i> , 2021, 64, 871-887.	1.0	19
14	Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice. <i>Scientific Reports</i> , 2019, 9, 17207.	1.6	18
15	Elevated Pressure Changes the Purinergic System of Microglial Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 16.	1.6	17
16	Different retinopathy phenotypes in type 2 diabetes predict retinopathy progression. <i>Acta Diabetologica</i> , 2021, 58, 197-205.	1.2	14
17	Microaneurysm Turnover in Mild Non-Proliferative Diabetic Retinopathy is Associated with Progression and Development of Vision-Threatening Complications: A 5-Year Longitudinal Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2142.	1.0	14
18	Melanopsin expression is an indicator of the well-being of melanopsin-expressing retinal ganglion cells but not of their viability. <i>Neural Regeneration Research</i> , 2016, 11, 1243.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Optical Coherence Tomography Angiography Metrics Monitor Severity Progression of Diabetic Retinopathy—3-Year Longitudinal Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2296.	1.0	12
20	Subtle thinning of retinal layers without overt vascular and inflammatory alterations in a rat model of prediabetes. <i>Molecular Vision</i> , 2018, 24, 353-366.	1.1	11
21	Glia-Mediated Retinal Neuroinflammation as a Biomarker in Alzheimer's Disease. <i>Ophthalmic Research</i> , 2015, 54, 204-211.	1.0	9
22	Ocular and Systemic Risk Markers for Development of Macular Edema and Proliferative Retinopathy in Type 2 Diabetes: A 5-Year Longitudinal Study. <i>Diabetes Care</i> , 2021, 44, e12-e14.	4.3	8
23	Retinal Neurodegeneration in Different Risk Phenotypes of Diabetic Retinal Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, .	1.4	8
24	Association between Neurodegeneration and Macular Perfusion in the Progression of Diabetic Retinopathy: A 3-Year Longitudinal Study. <i>Ophthalmologica</i> , 2022, 245, 335-341.	1.0	4
25	Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial. <i>Ophthalmologica</i> , 2022, 245, 80-90.	1.0	3
26	Characterisation of progression of macular oedema in the initial stages of diabetic retinopathy: a 3-year longitudinal study. <i>Eye</i> , 2023, 37, 313-319.	1.1	3
27	Characterization of One-Year Progression of Risk Phenotypes of Diabetic Retinopathy. <i>Ophthalmology and Therapy</i> , 2022, 11, 333-345.	1.0	3